bioretec

Agenda of the Annual General Meeting

- 1. Opening of the meeting
- 2. Calling the meeting to order
- 3. Election of persons to scrutinize the minutes and to supervise the counting of votes
- 4. Recording the legality of the meeting
- 5. Recording the attendance at the meeting and adoption of the list of votes
- 6. Presentation of the financial statements, consolidated financial statements and the report of the Board of Directors for the financial period 1 January 31 December 2021 and the CEO's review for the period
- 7. Presentation of the auditor's report
- 8. Approval of the financial statements, including the consolidated financial statements
- 9. Treatment of profit or loss
 - The Board of Directors of the company proposes that the Annual General Meeting resolve to credit the loss of EUR 5.947.718,62 for the financial period from 1 January to 31 December 2021 to the equity as profit/loss from preceding financial periods and that no dividend shall be distributed.
- 10. Resolution on the discharge from liability of the members of the Board of Directors and the CEO for the financial period from 1 January to 31 December 2021
- 11. Resolution on the remuneration of the members of the Board of Directors and the auditor
 - Five largest shareholders of the company mutually propose to the Annual General Meeting that the following remuneration will be paid to the members of the Board of Directors to be chosen for the term beginning at the end of the Annual General Meeting and ending at the end of the 2023 Annual General Meeting:
 - o EUR 2,500 per month for the chairman of the Board of Directors; and
 - o EUR 1,500 per month for the members of the Board of Directors.

Notwithstanding his possible election to the Board of Directors, the company may enter into a consultancy agreement with Tomi Numminen in respect of consulting services related to the funding processes of the company and commercialization of the company's products in the United States. The consultancy fee payable pursuant to such agreement shall not exceed EUR 7,500 per month.

- The Board of Directors of the company proposes to the Annual General Meeting that the auditor will be compensated as reasonably invoiced.
- 12. Resolution on the number of members of the Board of Directors and any alternates

bioretec

- According to the Articles of Association, the Board of Directors consists of a minimum of three (3) and a maximum of seven (7) members. The current number of board members is five.
- Five largest shareholders of the company mutually propose to the Annual General Meeting that five (5) ordinary members will be elected to the Board of Directors and that no alternates be elected.

13. Flection of members of the Board of Directors

- Five largest shareholders of the company mutually propose to the Annual General Meeting that Tomi Numminen, Michael Piccirillo, Sarah Fisher and Pekka Simula are re-elected as members and Päivi Malinen elected as a new member of the Board of Directors for a term starting at the end of the Annual General Meeting and expiring at the closing of the 2023 Annual General Meeting.

All board member candidates have given their consent for election.

14. Election of auditors

- The Board of Directors of the company proposes to the Annual General Meeting that auditing firm Ernst & Young Oy would be elected as auditor of the company until the closing of the 2022 Annual General Meeting. Auditing firm Ernst & Young has notified the company that it will appoint Erika Grönlund, Authorized Public Accountant, as the responsible auditor.
- 15. Authorisation of the Board of Directors to resolve on the issuance of shares and special rights entitling to shares
 - The Board of Directors proposes that the Annual General Meeting authorizes the Board of Directors to resolve on the issuance of shares, as well as the issuance of option rights and other special rights entitling to shares pursuant to Chapter 10 of the Finnish Companies Act, as follows:

Under the authorization, up to 5,000,000 (including the new shares to be issued based on the special rights) shares can be issued, which at the time of the proposal represents approximately 35 per cent of all outstanding company shares.

The shares or special rights entitling to shares can be issued in one or more tranches, either against or without payment. The shares issued under the authorization can be new shares or shares in the company's possession.

The authorization can be used for the financing or execution of acquisitions or other business arrangements, to strengthen the balance sheet and financial position of the company, for implementing the company's share-based incentive plans, or for other purposes determined by the Board of Directors.

Under the authorization, the Board of Directors may resolve upon issuing new shares, without consideration, to the company itself.

The Board of Directors is authorized to resolve on all terms for share issues and granting of special rights entitling to shares in the company. The Board of Directors is authorized to resolve on a directed share issue and issuance of special rights entitling to shares according to the shareholders' pre-empitive

bioretec

righst and/or in deviation from the shareholders' pre-emptive right, provided that there is a weighty financial reason for the company to do so.

The authorization is valid until the end of the next Annual General Meeting, however, no longer than until 30 June 2023. The authorization shall revoke previous unused share issue authorizations except for the authorization granted by the Annual General Meeting held on 26 June 2020 authorizing the Option Program 2020-1.

16. Proposal by the board of directors to grant option rights to the members of the board of directors

The board of directors of the company proposes to the Annual General Meeting of shareholders that the Annual General Meeting resolves to grant option rights to the members of the board of directors as set out below:

- 1. The Annual General Meeting of the company convening on 26 June 2020 authorized the board of directors to grant option rights (Option program 2020-1) ("Option Rights"). The Option Rights that may be granted pursuant to the authorization may entitle to up to 1,733,333 new shares in the company. Pursuant to the authorization, Option Rights can be given to the company's Key Employees, members of the Key Opinion Leader group and possibly also to members of the board of directors, as part of the company's incentive program to be decided by the board of directors. Pursuant to the authorization, the board of directors shall decide on to whom Option Rights shall be given and all the other terms and conditions related to the Option Rights. However, the general meeting of shareholders of the company shall decide on granting Option Rights for the members of the board of directors in case Option Rights are granted as remuneration for membership in the board of directors. Pursuant to the authorization, the Option Rights shall be given free of charge.
- 2. The board of directors proposes to the Annual General Meeting that the Annual General Meeting resolves to grant Option Rights entitling in aggregate to up to 106,666 new shares on the Terms and Conditions set out in Appendix 2 to members of the board of directors as set out below:

Subscriber	Option sub-	Option sub-	Option sub-	Number	Amount of
	group	group	group	of	shares
	2020-1A up	2020-1B up	2020-1C up	option	possible to
	to	to	to	rights in	be
				total up to	subscribed
					based on the
					option rights
Sarah Fisher	400.000	300.000	300.000	1.000.000	66.666
Päivi Malinen		300.000	300.000	600.000	40.000

17. Closing of the meeting